Endothelin receptor antagonist bosentan improves the dermal sclerosis in a patient with systemic sclerosis

The Australasian Journal of Dermatology
Akiko NishibuToshiyuki Yamamoto

Abstract

We report a case of systemic sclerosis with interstitial pneumonia and severe pulmonary hypertension treated with bosentan, an endothelin receptor antagonist. Within a short period of administration of the bosentan the skin sclerosis improved.

References

Apr 7, 2005·Current Medical Research and Opinion·Gianluigi GiannelliSalvatore Antonaci
Apr 7, 2005·Current Medical Research and Opinion·Philip J CowenJoubert Gama
Dec 13, 2005·The FEBS Journal·Angelika HorstmeyerThomas Krieg
Aug 8, 2007·Matrix Biology : Journal of the International Society for Matrix Biology·Xu Shi-WenAndrew Leask
Dec 9, 2008·European Journal of Dermatology : EJD·Toshiyuki Yamamoto
Feb 24, 2010·The Journal of Dermatology·Masatoshi Jinnin

❮ Previous
Next ❯

Citations

Aug 22, 2015·Seminars in Immunopathology·Jeannine GüntherGabriela Riemekasten

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.

© 2021 Meta ULC. All rights reserved